Search - tctmd.com

Displaying 1 - 20 of 117

Sort: Relevancy | Date

Presentation TCT 2025

Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs. HFpEF Presented

Presenter: JoAnn Lindenfeld

October 27, 2025

Presentation TCT 2025

TCT 586: Diuretic Management in Patients Treated with Greater Splanchnic Nerve Ablation for HFpEF: REBALANCE-HF Randomized Trial

Presenter: Sheldon E. Litwin

October 27, 2025

Presentation TCT 2025

TCT 532: Prevalence and Prognostic Value of Consensus-Defined Metabolic Hyperferritinemia in HFpEF Across Glucose Metabolism States

Presenter: Weicheng Ni

October 27, 2025

Presentation THT 2025

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Presenter: Marat Fudim

February 13, 2025

Presentation THT 2025

Stem Cell Based Therapies for HFpEF and HFrEF

Presenter: Sunjay Kushal

February 12, 2025

Presentation THT 2025

Greater Splanchnic Nerve Ablation for HFpEF

Presenter: Sheldon Litwin

February 12, 2025

Presentation THT 2025

HFpEF: Can Image Phenotyping Help for Prognostication and Therapy DEevelopment

Presenter: Jonathan Cunningham

February 12, 2025

Presentation THT 2025

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

Presenter: Phuuwadith Wattanachayakul

February 12, 2025

Presentation THT 2025

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Presenter: Carolyn Lam

February 12, 2025

Presentation THT 2025

Practical Challenges: Management of Hyperkalemia and Hypokalemia

Presenter: Orly Vardeny

February 12, 2025

Presentation THT 2025

FINEARTS-HF Design and Principal Results in Context

Presenter: Akshay Desai

February 12, 2025

Presentation THT 2025

Key Secondary Analyses of FINEARTS-HF: What have we learned?

Presenter: Muthiah Vaduganathan

February 12, 2025

Presentation THT 2025

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

Presenter: JoAnn Lindenfeld

February 12, 2025

Presentation THT 2025

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

Presenter: Sanjiv Shah

February 12, 2025

Presentation THT 2025

HFpEF Hidden in Plain Sight: Undertreatment of Patients With Negative Screening for Suspected Amyloidosis

Presenter: Solenn Dal Soglio

February 12, 2025

Presentation THT 2025

How Does Weight Loss Improve Hemodynamics in Patients With HFpEF

Presenter: Barry Borlaug

February 12, 2025

Presentation THT 2025

Weight Loss Improves Outcome in HFpEF: Summarizing the Clinical Evidence

Presenter: Marco Metra

February 12, 2025

Presentation THT 2025

Inflammation and HFpEF: Rationale for HERMES

Presenter: Mark Petrie

February 12, 2025

Presentation THT Abstracts 2025

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

Presenter: Phuuwadith Wattanachayakul

February 11, 2025

Presentation THT Abstracts 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Advertisement

Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs. HFpEF Presented

TCT 586: Diuretic Management in Patients Treated with Greater Splanchnic Nerve Ablation for HFpEF: REBALANCE-HF Randomized Trial

TCT 532: Prevalence and Prognostic Value of Consensus-Defined Metabolic Hyperferritinemia in HFpEF Across Glucose Metabolism States

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Stem Cell Based Therapies for HFpEF and HFrEF

Greater Splanchnic Nerve Ablation for HFpEF

HFpEF: Can Image Phenotyping Help for Prognostication and Therapy DEevelopment

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Practical Challenges: Management of Hyperkalemia and Hypokalemia

FINEARTS-HF Design and Principal Results in Context

Key Secondary Analyses of FINEARTS-HF: What have we learned?

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

HFpEF in Focus: The Scientific Rationale for the Confirmatory RESPONDER HF Trial

HFpEF Hidden in Plain Sight: Undertreatment of Patients With Negative Screening for Suspected Amyloidosis

How Does Weight Loss Improve Hemodynamics in Patients With HFpEF

Weight Loss Improves Outcome in HFpEF: Summarizing the Clinical Evidence

Inflammation and HFpEF: Rationale for HERMES

Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content